1. Cyhoeddwyd

   Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

   Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

2. Cyhoeddwyd

   Introduction to pharmaeconomics

   Hughes, D. & Hughes, D. A., 1 Gorff 2004.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

   Hughes, D. & Hughes, D. A., 1 Mai 2002.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Patient compliance and pharmacoeconomics

   Hughes, D. & Hughes, D. A., 1 Hyd 2001.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

   Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   The difference between effectiveness and efficacy of antimalarial drugs in Kenya.

   Hughes, D., Amin, A. A., Hughes, D. A., Marsh, V., Abuya, T. O., Kokwaro, G. O., Winstanley, P. A., Ochala, S. A. & Snow, R. W., 1 Medi 2004, Yn: Tropical Medicine and International Health. 9, 9, t. 967-974

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

8. Cyhoeddwyd

   Biosimilars: Evidential standards for health technology assessment.

   Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

   Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

   Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

10. Cyhoeddwyd

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

11. Cyhoeddwyd

    Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

    Hughes, D., Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., Van Eker, D., Stevens, L., Hawkins, K., Toh, C. H., Kamali, F., Daly, A. K., Fitzmaurice, D., Coffey, A., Williamson, P. R., Park, B. K., Deloukas, P. & Pirmohamed, M., 1 Hyd 2009, Yn: Pharmacogenetics and Genomics. 19, 10, t. 800-812

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    The development of a QALY measure for epilepsy: NEWQOL-6D

    Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 Mai 2012, Yn: Epilepsy and Behavior. 24, 1, t. 36-43

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

13. Cyhoeddwyd

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

14. Cyhoeddwyd

    Defining rewardable innovation in drug therapy

    Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Ebr 2012, Yn: Nature Reviews Drug Discovery. 11, t. 253-254

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

15. Cyhoeddwyd

    Statistical comments are unfounded.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Hyd 2001, Yn: Health Economics. 10, 7, t. 601-615

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

17. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

18. Cyhoeddwyd

    Welsh Health Economics Network (WHEN): Scoping Report.

    Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

19. Cyhoeddwyd

    Estimating Drug Costs in Economic Evaluations in Ireland and the UK: An Analysis of Practice and Research Recommendations.

    Hughes, D., Hughes, D. A., Tilson, L. & Drummond, M. F., 1 Mai 2009, Yn: Pharmacoeconomics. 27, 8, t. 635-643

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

22. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

23. Cyhoeddwyd

    Quantitative risk-benefit analysis

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Tach 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

27. Cyhoeddwyd

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

29. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

30. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Warfarin pharmacogenetics: Economic considerations.

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 11, t. 899-902

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

32. Cyhoeddwyd

    Public funding of drugs for orphan diseases

    Hughes, D. & Hughes, D. A., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

    Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

34. Cyhoeddwyd

    Multiple imputation of multiple multi-item scales when a full imputation model is infeasible

    Hughes, D., Plumpton, C. O., Morris, T., Hughes, D. A. & White, I. R., 26 Ion 2016, Yn: BMC Research Notes. 9, 45, t. 1-15

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

35. Cyhoeddwyd

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

37. Cyhoeddwyd

    Engaging with the MRC Methodology Hubs – NWHTMR.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

38. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

40. Cyhoeddwyd

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Awst 2002, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, t. 327-335

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

41. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

42. Cyhoeddwyd

    Evaluation of a consultant audit and feedback programme to improve the quality of antimicrobial prescribing in acute medical admissions

    Hughes, D., Roberts, E., Dawoud, D. M., Hughes, D. A. & Cefai, C., 1 Hyd 2015, Yn: International Journal of Pharmacy Practice. 23, 5, t. 333-339

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

43. Cyhoeddwyd

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

44. Cyhoeddwyd

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

45. Cyhoeddwyd

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

46. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

47. Cyhoeddwyd

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

48. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Medi 2001, Yn: Value in Health. 4, 6, t. 489

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

49. Cyhoeddwyd

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

50. Cyhoeddwyd

    Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

    Hughes, D., Pink, J., Lane, S., Pirmohamed, M. & Hughes D.A., N. V., 31 Hyd 2011, Yn: British Medical Journal. 343, t. 1-14

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

51. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

52. Cyhoeddwyd

    A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)

    Hughes, D., Ramanan, A., Dick, A. D., Benton, D., Compeyrot-Lacassagne, S., Dawoud, D., Hardwick, B., Hickey, H., Hughes, D. A., Jones, A., Woo, P., Edelsten, C., Beresford, M. W. & The SYCAMORE Trail Management Group, N. V., 9 Ion 2014, Yn: Trials. 15, 14

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

53. Cyhoeddwyd

    The problem of orphan drugs

    Hughes, D., Ferner, R. E. & Hughes, D. A., 16 Tach 2010, Yn: British Medical Journal. 341, t. 335-341

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

54. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

55. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

56. Cyhoeddwyd

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

57. Cyhoeddwyd

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

58. Cyhoeddwyd

    Drugs for exceptionally rare diseases: do they deserve special status for funding?

    Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

59. Cyhoeddwyd

    Is exercise effective in promoting mental well-being in older age? A systematic review.

    Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T. & Woods, R. T., 1 Awst 2010, Yn: Aging and Mental Health. 14, 6, t. 652-669

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

60. Cyhoeddwyd

    Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

    Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

61. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

62. Cyhoeddwyd

    Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Ion 2001, Yn: Pharmacoeconomics. 19, 11, t. 1069-1077

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

63. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008

    Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe

64. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

65. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

66. Cyhoeddwyd

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

67. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

68. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

69. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

70. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

71. Cyhoeddwyd

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

72. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

73. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A109

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

74. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

75. Cyhoeddwyd

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

76. Cyhoeddwyd

    Pharmacogenetic tests: the need for a level playing field

    Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Ion 2013, Yn: Nature Reviews Drug Discovery. 12, 3-4

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

77. Cyhoeddwyd

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

78. Cyhoeddwyd

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

79. Cyhoeddwyd

    Abolition of prescription copayments in Wales: an observational study on dispensing rates.

    Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Awst 2010, Yn: Value in Health. 13, 5, t. 675-680

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

80. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

81. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003, Yn: Value in Health. 6, 6, t. 749

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

82. Cyhoeddwyd

    Patient-focused drug development methods for benefit-risk assessments: A case study using discrete choice experiment for antiepileptic drugs

    Holmes, E. A. F., Plumpton, C., Baker, G. A., Jacoby, A., Ring, A., Williamson, P., Marson, A. & Hughes, D. A., Maw 2019, Yn: Clinical Pharmacology and Therapeutics. 105, 3, t. 672-683 12 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

83. Cyhoeddwyd

    Developing an alternative care pathway for emergency ambulance responses for adults with epilepsy: A Discrete Choice Experiment to understand which configuration service users prefer. Part of the COLLABORATE project

    Holmes, E., Dixon, P., Mathieson, A., Ridsdale, L., Morgan, M., McKinlay, A., Dickson, J., Goodacre, S., Jackson, M., Foster, D., Hardman, K., Bell, S., Marson, A., Hughes, D. & Noble, A. J., Ebr 2024, Yn: Seizure: European Journal of Epilepsy. 118, t. 28-37 10 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

84. Cyhoeddwyd

    Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care

    Holmes, E., Harris, S. D., Hughes, A., Craine, N. & Hughes, D., 7 Rhag 2018, Yn: Antibiotics. 7, 4, 19 t., 106.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

85. Cyhoeddwyd

    A model-based cost-utility analysis of an automated notification system for deteriorating patients on general wards

    Holmes, E., Hughes, D. & Subbe, C., 2 Mai 2024, Yn: PLoS ONE. 19, 5, t. e0301643 e0301643.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

86. Cyhoeddwyd

    Patient preferences for outcomes in clinical trials: implications for medicines optimization

    Holmes, E., Marson, A. G. & Hughes, D., 8 Mai 2017, Yn: Trials. 18 (Suppl 1), O18, t. 192 1 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

87. Cyhoeddwyd

    Challenges for economic evaluation of strategies to contain antimicrobial resistance

    Holmes, E. & Hughes, D., 27 Medi 2019, Yn: Antibiotics. 8, 4, 8 t., 166.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl › adolygiad gan gymheiriaid

88. Cyhoeddwyd

    What influences persistence with medicines? A multinational discrete choice experiment of 2549 patients

    Holmes, E. A., Morrison, V. L. & Hughes, D., Awst 2016, Yn: British Journal of Clinical Pharmacology. 82, 2, t. 522-531

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

89. Cyhoeddwyd

    A new taxonomy for describing and defining adherence to medications

    Holmes, E. A., Hughes, D., Morrison, V. L., Vrijens, B., De Geest, S., Hughes, D. A., Prezemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J. K. & Urquhart, J., 1 Mai 2012, Yn: British Journal of Clinical Pharmacology. 73, 5, t. 691-705

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

90. Cyhoeddwyd

    New advice on switching antiepileptic drugs might be a false economy

    Holmes, E. A., Plumpton, C. O., Hughes, D., Holmes, E., Plumpton, C., Duerden, M., Marson, T. & Hughes, D. A., 16 Rhag 2013, Yn: British Medical Journal. 347

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

91. Cyhoeddwyd

    Predicting Adherence to Medications Using Health Psychology Theories: A Systematic Review of 20 Years of Empirical Research

    Holmes, E. A., Morrison, V. L. & Hughes, D., 8 Rhag 2014, Yn: Value in Health. 17, 8, t. 863-876

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

92. Cyhoeddwyd

    Combining model-based clinical trial simulation, pharmacoeconomics and value of information to optimize trial design

    Hill-McManus, D. & Hughes, D., Ion 2021, Yn: CPT: Pharmacometrics & Systems Pharmacology . 10, 1, t. 75-83 9 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

93. Cyhoeddwyd

    Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data

    Hill-McManus, D. & Hughes, D., Meh 2022, Yn: British Journal of Clinical Pharmacology. 88, 6, t. 2782-2792 11 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

94. Cyhoeddwyd

    Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development

    Hill-McManus, D., Marshall, S., Liu, J., Willke, R. & Hughes, D., Gorff 2021, Yn: Clinical Pharmacology and Therapeutics. 110, 1, t. 49-63

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

95. Cyhoeddwyd

    Impact of non-adherence and flare resolution on the cost effectiveness of treatments for gout: Application of a linked pharmacometric/pharmacoeconomic model

    Hill-McManus, D., Marshall, S., Soto, E., Lane, S. & Hughes, D., Rhag 2018, Yn: Value in Health. 21, 12, t. 1373-1381

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

96. Cyhoeddwyd

    Impact of non-adherence on the safety and efficacy of uric acid lowering therapies in the treatment of gout

    Hill McManus, D., Soto, E., Marshall, S., Lane, S. & Hughes, D., Ion 2018, Yn: British Journal of Clinical Pharmacology. 84, 1, t. 142-152

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

97. Cyhoeddwyd

    Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout

    Hill McManus, D., Marshall, S., Soto, E. & Hughes, D., Medi 2019, Yn: Clinical Pharmacology and Therapeutics. 106, 3, t. 652-660

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

98. Cyhoeddwyd

    Is there a role for Natural Desiccated Thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a Consecutive Case Series

    Heald, A., Premawardhana, L., Taylor, P., Okosieme, O., Bangi, T., Devine, H., Livingston, M., Javed, A., Moreno, G. Y. C., Watt, T., Stedman, M. & Hughes, D., 28 Rhag 2021, Yn: International Journal of Clinical Practice. 75, 12, e14967.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

99. Cyhoeddwyd

    Generalisability and Cost-Impact of Antibiotic-Impregnated Central Venous Catheters for Reducing Risk of Bloodstream Infection in Paediatric Intensive Care Units in England

    Harron, K., Mok, Q., Hughes, D., Muller-Pebody, B., Parslow, R., Ramnarayan, P. & Gilbert, R., 21 Maw 2016, Yn: PLoS ONE. 11, 3, t. e0151348

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

100. Cyhoeddwyd

     CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children

     Harron, K., Mok, Q., Dwan, K., Ridyard, C., Mott, T., Millar, M., Ramnarayan, P., Tibby, S. M., Muller-Pebody, B., Hughes, D., Gamble, C. & Gilbert, R. E., Maw 2016, Yn: Health Technology Assessment. 20, 18

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid